Cargando…

Radiotheranostic Agents in Hematological Malignancies

Radioimmunotherapy (RIT) is a cancer treatment that combines radiation therapy with tumor-directed monoclonal antibodies (Abs). Although RIT had been introduced for the treatment of CD20 positive non-Hodgkin lymphoma decades ago, it never found a broad clinical application. In recent years, research...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caers, Jo, Duray, Elodie, Vrancken, Louise, Marcion, Guillaume, Bocuzzi, Valentina, De Veirman, Kim, Krasniqi, Ahmet, Lejeune, Margaux, Withofs, Nadia, Devoogdt, Nick, Dumoulin, Mireille, Karlström, Amelie Eriksson, D’Huyvetter, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294596/ https://www.ncbi.nlm.nih.gov/pubmed/35865548 http://dx.doi.org/10.3389/fimmu.2022.911080

Ejemplares similares

A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma
por: Duray, Elodie, et al.
Publicado: (2021)

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
por: Dekempeneer, Yana, et al.
Publicado: (2016)

Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases
por: Puttemans, Janik, et al.
Publicado: (2019)

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2021)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
por: Lejeune, Margaux, et al.
Publicado: (2020)

Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
por: Lejeune, Margaux, et al.
Publicado: (2021)

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
por: D’Huyvetter, Matthias, et al.
Publicado: (2014)

Theranostics in immuno-oncology using nanobody derivatives
por: Lecocq, Quentin, et al.
Publicado: (2019)

Dual Imaging Gold Nanoplatforms for Targeted Radiotheranostics
por: Silva, Francisco, et al.
Publicado: (2020)

Radiotheranostics Practice in India- Advancing to Precision Oncology
por: Kumar, Rakesh, et al.
Publicado: (2022)

GRPR-targeting radiotheranostics for breast cancer management
por: D’Onofrio, Alice, et al.
Publicado: (2023)

Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model
por: Ertveldt, Thomas, et al.
Publicado: (2022)

Translating Research for the Radiotheranostics of Nanotargeted (188)Re-Liposome
por: Chang, Chih-Hsien, et al.
Publicado: (2021)

Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging
por: Duan, Heying, et al.
Publicado: (2022)

Editorial: Radiotheranostics: From basic research to clinical application
por: Gareev, Kamil G., et al.
Publicado: (2023)

Targeted Radionuclide Therapy with A (177)Lu-labeled Anti-HER2 Nanobody
por: D'Huyvetter, Matthias, et al.
Publicado: (2014)

The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy
por: Puttemans, Janik, et al.
Publicado: (2022)

Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy
por: Funeh, Cyprine Neba, et al.
Publicado: (2023)

Cross‐Isotopic Bioorthogonal Tools as Molecular Twins for Radiotheranostic Applications
por: Rosecker, Veronika, et al.
Publicado: (2019)

Stability Estimation of Gallium Complexes of DOTA Derivatives for Radiotheranostic Applications
por: Suzuki, Hiroyuki, et al.
Publicado: (2022)

Integrative Analysis of Proteomics and Transcriptomics Reveals Endothelin Receptor B as Novel Single Target and Identifies New Combinatorial Targets for Multiple Myeloma
por: Lejeune, Margaux, et al.
Publicado: (2023)

Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics
por: Martin, Marcel, et al.
Publicado: (2023)

Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts
por: Muller, Joséphine, et al.
Publicado: (2019)

Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application
por: Müller, Cristina, et al.
Publicado: (2018)

Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions
por: Heidari, Pedram, et al.
Publicado: (2018)

Synthesis and Evaluation of a Dimeric RGD Peptide as a Preliminary Study for Radiotheranostics with Radiohalogens
por: Echigo, Hiroaki, et al.
Publicado: (2021)

Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease
por: Muller, Joséphine, et al.
Publicado: (2018)

Assessment of mouse-specific pharmacokinetics in kidneys based on (131)I activity measurements using micro-SPECT
por: Vargas, Clarita Saldarriaga, et al.
Publicado: (2022)

Network Analysis Examining Intrahospital Traffic of Patients With Traumatic Hip Fracture
por: Secor, Elizabeth A., et al.
Publicado: (2023)

The antigen‐binding moiety in the driver's seat of CARs
por: Hanssens, Heleen, et al.
Publicado: (2021)

India's Growing Nuclear Medicine Infrastructure and Emergence of Radiotheranostics in Cancer Care: Associated Challenges and the Opportunities to Collaborate
por: Singh, Baljinder, et al.
Publicado: (2023)

Preclinical Targeted α- and β(−)-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
por: Puttemans, Janik, et al.
Publicado: (2020)

Predictors of transfer from a remote trauma facility to an urban level I trauma center for blunt splenic injuries: a retrospective observational multicenter study
por: McGraw, Constance, et al.
Publicado: (2022)

Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors
por: Hu, Kuan, et al.
Publicado: (2022)

Bi-Functional Radiotheranostics of (188)Re-Liposome-Fcy-hEGF for Radio- and Chemo-Therapy of EGFR-Overexpressing Cancer Cells
por: Huang, Yi-Shu, et al.
Publicado: (2021)

Radiochemical and Biological Evaluation of 3p-C-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics
por: Murce, Erika, et al.
Publicado: (2023)

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts
por: Faict, Sylvia, et al.
Publicado: (2018)

Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33
por: Romão, Ema, et al.
Publicado: (2020)

A First Report on [(18)F]FPRGD(2) PET/CT Imaging in Multiple Myeloma
por: Withofs, Nadia, et al.
Publicado: (2017)

Cancer radiotheranostics targeting carbonic anhydrase-IX with (111)In- and (90)Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy
por: Iikuni, Shimpei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hu2av7idl94apivjm4p8815tui